Design of Potent, Selective, and Orally Bioavailable Inhibitors of Cysteine Protease Cathepsin K

Journal of Medicinal Chemistry

Volumn 47, Issue 3, 2004, Pages 588-599

  Tavares, Francis X ^a   Boncek, Virginia ^a,b   Deaton, David N ^a   Hassell, Anne M ^a   Long, Stacey T ^a   Miller, Aaron B ^a   Payne, Alan A ^a   Miller, Larry R ^a   Shewchuk, Lisa M ^a   Wells Knecht, Kevin ^a   Willard Jr , Derril H ^a   Wright, Lois L ^a   Zhou, Hui Qiang ^a  

^a GLAXOSMITHKLINE   (United States)

^b 111 Hermann Building ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDE; CATHEPSIN; CATHEPSIN K; CATHEPSIN K INHIBITOR; CATHEPSIN L; CATHEPSIN S; CATHEPSIN V; CYSTEINE PROTEINASE; CYSTEINE PROTEINASE INHIBITOR; HETEROCYCLIC COMPOUND; PARATHYROID HORMONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MATRIX; CRYSTALLOGRAPHY; DISEASE MODEL; DRUG BINDING; DRUG DESIGN; DRUG IDENTIFICATION; DRUG POTENCY; DRUG STRUCTURE; ELECTRONICS; HUMAN; HYPERCALCEMIA; MALE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; RAT; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ADMINISTRATION, ORAL; AMIDES; ANIMALS; BIOLOGICAL AVAILABILITY; CALCIUM; CATHEPSINS; CRYSTALLOGRAPHY, X-RAY; CYSTEINE PROTEINASE INHIBITORS; HUMANS; KETONES; MALE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; OSTEOPOROSIS; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 9144241615     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030373l     Document Type: Article

References (55)

1. (a) Marcus, R.; Feldman, D.; Kelsey, J. In Osteoporosis, 1st ed.; Academic Press: New York, 1996.
2. (b) Baron, R. Anatomy and Ultrastructure of Bone. In Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 1st ed.; Favus, M. J., Ed.; American Society for Bone and Mineral Research: Kelseyville, CA, 1990; pp 3-9.
3. (a) Broemme, D.; Okamoto, K. Human cathepsin O2, a novel cysteine protease highly expressed in osteoclastomas and ovary. Molecular cloning, sequencing and tissue distribution. Biol. Chem. Hoppe-Seyler 1995, 376, 379-384.
4. (b) Drake, F. H.; Dodds, R. A.; James, I. A.; Connor, J. R.; Debouck, C. ; Richardson, S.; Lee-Rykaczewski, L.; Coleman, L.; Riemann, D.; Barthlow, R.; Hastings, G.; Gowen, M. Cathepsin K, but not cathepsins B, L or S is abundantly expressed in human osteoclasts. J. Biol. Chem. 1996, 271, 12511-12516.
5. (c) Littlewood-Evans, A.; Kokubo, T.; Ishibashi, O.; Inaoka, T.; Wlodarski, B.; Gallagher, J. A.; Bilbe, G. Localization of cathepsin K in human osteoclasts by in situ hybridization and immunohistochemistry. Bone 1997, 20, 81-86.
6. (d) Shi, G.-P.; Chapman, H. A.; Bhairi, S. M.; DeLeeuw, C.; Reddy, V. Y. ; Weiss, S. J. Molecular cloning of human cathepsin O, a novel endoproteinase and homologue of rabbit OC2. FEBS Lett. 1995, 357, 129- 134.
7. Inui, T.; Ishibashi, O.; Inaoka, T.; Origane, Y.; Kumegawa, M.; Kokubo, T.; Yamaura, T. Cathepsin K antisense oligodeoxynucleotide inhibits osteoclastic bone resorption. J. Biol. Chem. 1997, 272, 8109-8112.
8. (a) Gelb, B. D.; Moissoglu, K.; Zhang, J.; Martignetti, J. A.; Broemme, D.; Desnick, R. J. Cathepsin K: isolation and characterization of the murine cDNA and genomic sequence, the homologue of the human pycnodysostosis gene. Biochem Mol. Med. 1996, 59, 200-206.
9. (b) Johnson, M. R.; Polymeropoulos, M. H.; Vos, H. L.; Oritz de Luna, R. I.; Francomano, C. A. A nonsense mutation in the cathepsin K gene observed in a family with pycnodysostosis. Genome Res. 1996, 6, 1050-1055.
10. (c) Gelb, B. D.; Shi, G.-P.; Chapman, H. A.; Desnick, R. J. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 1996, 273, 1236-1238.
11. (d) Motyckova, G.; Fisher, D. Pycnodysostosis: role and regulation of cathepsin K in osteoclast function and human disease. Curr. Mol. Med. 2002, 2 (5), 407-421.
12. (a) Saftig, P.; Hunziker, E.; Wehmeyer, O.; Jones, S.; Boyde, A.; Rommerskirch, W.; Detlev, J. D.; Schu, P.; von Figura, K. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin K deficient mice. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 13453-13458.
13. (b) Gowen, M.; Lazner, F.; Dodds, R.; Kapadia, R.; Field, J.; Tavaria, M.; Bertoncello, I.; Drake, F.; Zavarselk, S.; Tellis, I.; Hertzog, P.; Debouck, C.; Kola, I. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J. Bone Miner. Res. 1999, 14, 1654-1663.
14. (a) James, I. E.; Marquis, R. W.; Blake, S. M.; Hwang, S. M.; Gress, C. J.; Ru, Y.; Zembryki, D.; Yamashita, D. S.; McQueney, M. S.; Tomaszek, T. A.; Oh, H. J.; Gowen, M.; Veber, D. F.; Lark, M. W. Potent and Selective Cathepsin L Inhibitors Do Not Inhibit Osteoclast Resorption in vitro. J. Biol. Chem. 2001, 276 (15), 11507-11511.
15. (b) Stroup, G. B.; Lark, M. V.; Veber, D. F.; Bhattacharya, A.; Blake, S.; Dare, L. C.; Erhard, K. F.; Hoffman, S. J.; James, I. E.; Marquis, R. W.; Ru, Y.; Vasko-Moser, J. A.; Smith, B. R.; Tomaszek, T.; Gowen, M. Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate. J. Bone Miner. Res. 2001, 16 (10), 1739-1746.
16. Hashimoto, Y.; Kakegawa, H.; Narita, Y.; Hachiya, Y.; Hayakawa, T.; Kos, J.; Turk, V.; Katunuma, N. Significance of cathepsin B accumulation in synovial fluid of rheumatoid arthritis. Biochem. Biophys. Res. Commun. 2001, 283 (2), 334-339.
17. (b) Szpaderska, A. M.; Frankfater, A. An intracellular form of Cathepsin B contributes to invasiveness in cancer. Cancer Res. 2001, 61 (8), 3493-3500.
18. (c) Greenspan, P. D.; Clark, K. L.; Tommasi, R. A.; Cowen, S. D.; McQuire, L. W.; Farley, D. L.; Van Duzer, J. H.; Goldberg, R. L.; Zhou, H.; Du, Z.; Fitt, J. J.; Coppa, D. E.; Fang, Z.; Macchia, W.; Zhu, L.; Michael, P. Identification of dipeptidyl nitriles as potent and selective inhibitors of cathepsin B through structure-based drug design. J. Med. Chem. 2001, 44, 4524-4534.
19. (a) Turk, B.; Turk, D.; Turk, V. Review: Lysosomal cysteine proteases: more than scavengers. Biochim. Biophys. Acta 2000, 1477 (1-2), 98-111.
20. (b) Buhling, F.; Fengler, A.; Brandt, W.; Welte, T.; Ansorge, S.; Nagler, D. K. Review: Novel cysteine proteases of the papain family. Adv. Exp. Med. Biol. 2000, 477, 241-254.
21. Turk, V.; Turk, B.; Turk, D. Review: Lysosomal cysteine proteases: facts and opportunities. EMBO J. 2001, 20 (17), 4629-4633.
22. (a) Yamashita, Dennis S.; Dodds, Robert A. Cathepsin K and the design of inhibitors of cathepsin K. Current Pharmaceutical Design 2000, 6 (1), 1-24.
23. (b) Leung, D.; Abbenante, G.; Fairlie, D. Protease inhibitors: current status and future prospects. J. Med. Chem. 2000, 43, 305-341.
24. (b) Schirmeister, T.; Otto, H. Cysteine proteases and their inhibitors. Chem Rev. 1997, 97, 133-171.
25. Votta, B. J.; Levy, M. A.; Badger, A.; Bradbeer, J.; Dodds, R. A.; James, I. E.; Thompson, S.; Bossard, M. J.; Carr, T.; Conner, J. R.; Tomaszek, T. A.; Szewczuk, L.; Drake, F. H.; Veber, D. F.; Gowen, M. Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo. J. Bone Miner. Res. 1997, 12, 1396-1406.
26. (b) Yasuma, T.; Oi, S.; Choh, N.; Nomura, T.; Furuyama, N.; Nishimura, A.; Fujisawa, Y.; Sohda, T. Synthesis of peptide aldehyde derivatives as selective inhibitors of human cathepsin L and their inhibitory effect on bone resorption. J. Med. Chem. 1995, 41, 4301-4308.
27. (c) Karanewsky, D. S.; Bai, X.; Linton, S. D.; Krebs, J. F.; Wu, J.; Pham, B.; Tomaselli, K. J. Conformationally constrained inhibitors of caspase-1 (interleukin-1â converting enzyme) and of the human CED-3 homologue caspase-3 (CPP32, apopain). Bioorg. Med. Chem. Lett. 1998, 8, 2757-2762.
28. 13C NMR evidence for a thioimidate ester adduct. J. Am. Chem. Soc. 1956, 108, 1350 1351.
29. (b) Brisson, J.-R.; Carey, P. R.; Storer, A. C. Benzoyl-amidoacetonitrile is bound as a thioimidate in the active site of papain. J. Biol. Chem. 1986, 261, 9087-9089.
30. (c) Liang, T.-C.; Abeles, R. H. Inhibition of papain by nitriles: mechanistic studies using NMR and kinetic measurements. Arch. Biochem. Biophys. 1987, 252, 626-634.
31. (a) Ando, R.; Morinaka, Y. A new class of proteinase inhibitor. Cyclopropenone-containing inhibitor of papain. J. Am. Chem. Soc. 1993, 115, 1174-1175.
32. (b) Ando, R.; Sakaki, T.; Morinaka, Y.; Takahashi, C.; Tamao, Y.; Yoshii, N.; Katayama, S.; Saito, K.; Tokuyama, H.; Isaka, M.; Nakamura, E. Cyclopropenone-containing cysteine proteinase inhibitors. Synthesis and enzyme inhibitory activities. Bioorg. Med. Chem. 1999, 7, 571-579.
33. (a) Majalli, A. M. M.; Chapman, K. T.; MacCoss, M.; Thornberry, N. A.; Peterson, E. P. Activated ketones as potent reversible inhibitors of interleukin-1α converting enzyme. Bioorg. Med. Chem. Lett. 1994, 4, 1965-1968.
34. (b) Yamashita, D. S.; Smith, W. W.; Zhao, B.; Janson, C. A.; Tomaszek, T. A.; Bossard, M. A.; Levy, M. A.; Oh, H.-J.; Carr, T. J.; Thompson, S. T.; Ijames, C. F.; Carr, S. A.; McQueney, M.; D'Alessio, K. J.; Amegadzie, B. Y.; Hanning, C. R.; Abdel-Meguid, S.; DesJarlais, R. L.; Gleason, J. G.; Veber, D. F. Structure and design of potent and selective cathepsin K inhibitors. J. Am. Chem. Soc. 1997, 119, 11351-11352.
35. (c) DesJarlais, R. L.; Yamashita, D. S.; Oh, H.-J.; Uzinskas, I. N.; Erhard, K. F.; Allen, A. C.; Haltwanger, R. C.; Zhao, B.; Smith, W. W.; Abdel-Meguid, S. S.; D'Allesio, K.; Janson, C. A.; McQueney, M. S.; Tomaszek, T. A.; Levy, M. A.; Veber, D. F. Use of X-ray cocrystal structures and molecular modeling to design potent and selective non-peptide inhibitors of cathepsin K. J. Am. Chem. Soc. 1913, 35, 9114-9115.
36. (d) Marquis, R. W.; Ru, Y.; LoCastro, S. M.; Zeng, J.; Yamashita, D. S.; Oh, H.-J.; Erhard, K. F.; Davis, L. D.; Tomaszek, T. A.; Tew, D.; Salyers, K.; Proksch, J.; Ward, K.; Smith, B.; Levy, M.; Cummings, M. D.; Haltiwanger, R. C. ; Trescher, G.; Wang, B.; Hemling, M. E.; Quinn, C. J.; Cheng, H.-Y.; Lin, F.; Smith, W. W.; Janson, C. A.; Zhao, B.; McQueney, M. S.; D'Alessio, K.; Lee, C.-P.; Marzulli, A.; Dodds, R. A.; Blake, S.; Hwang, S.-M.; James, I. E.; Gress, C. J.; Bradley, B. R.; Lark, M. W.; Gowen, M.; Veber, D. F. Azepanone-Based Inhibitors of Human and Rat Cathepsin K. J. Med. Chem. 2001, 44, 1380-1395.
37. (a) Hu, L.-Y.; Abeles, R. H. Inhibition of cathepsin B and papain by peptidyl α-keto esters, α-keto amides α-diketones and α-keto acids. Arch. Biochem. Biophys. 1990, 281, 271-274.
38. (b) Li, Z.; Patil, G. S.; Golubski, Z. E.; Hori, H.; Tehrani, K.; Foreman, J. E.; Eveleth, D. D.; Bartus, R. T.; Powers, J. C. Peptide R-keto ester, R-keto amide, and R-keto acid inhibitors of calpains and other cysteine proteases. J. Med. Chem. 1993, 36, 3472-3480.
39. (c) Harbeson, S. L.; Abelleira, S. M.; Akiyama, A.; Barrett III, R.; Carroll, R. M.; Straub, J. A.; Tkacz, J. N.; Wu, C.; Musso, G. F. Stereospecific synthesis of peptidyl α-keto amides as inhibitors of calpain. J. Med. Chem. 1994, 37, 2918-2929.
40. Altmann E.; Renaud, J.; Green, J.; Farley, D.; Cutting, B.; Jahnke, W. Arylaminoethyl amides as novel noncovalent cathepsin K inhibitors. J. Med. Chem. 2002, 45 (12) 2352-2354.
41. Cacciola, Joseph; Fevig, John M.; Stouten, Pieter F. W.; Alexander, Richard S.; Knabb, Robert M.; Wexler, Ruth R. Synthesis and activity studies of conformationally restricted α-ketoamide factor Xa inhibitors. Bioorg. Med. Chem. Lett. 2000, 10 (11), 1253-1256.
42. Rosenthal, K.; Karlström, A.; Undén, A. The 2,4-Dimethylpent-3-yloxycarbonyl (Doc) group as a new, nucleophile-resistant protecting group for tyrosine in solid-phase peptide synthesis. Tetrahedron Lett., 1997, 38 (6), 1075-1078
43. Wasserman, Harry H.; Ho, Wen-Bin. (Cyanomethylene)phosphoranes as novel carbonyl 1,1-dipole synthons: An efficient synthesis of α-keto acids, esters, and amides. J. Org. Chem. 1994, 59 (16), 4364-6.
44. Dorgan, Roderick J.; Parrick, J.; Hardy, Christopher, R. The Preparation of 1-protected-1H-pyrazolo[3,4-b]pyridines and attempts to move the 1-substituent. J. Chem. Soc., Perkin Trans. 1 1980, 938-942.
45. Frigola, J.; Colombo, A.; Pares, J.; Martinez, L.; Sagarra, R.; Roser, R. Synthesis, structure and inhibitory effects on cyclooxygenase, lipoxygenase, thromboxane synthetase and platelet aggregation of 3-amino-4,5-dihydro-1H-pyrazole derivatives. Eur. J. Med. Chem. Chim. Ther. 1989, 24, 435-446.
46. Ege, G.; Franz, H. Reactions with diazoazoles Part VI. Unequivocal synthesis of 3-methyl-3H-azolotetrazoles. J. Heterocycl. Chem. 1982, 18, 1267-1273.
47. (a) Sharp, K. Entropy-enthalpy compensation: Fact or artifact? Protein Sci. 2001, 10, 661-667.
48. (b) Liu, L.; Guo, Q.-X. Isokinetic relationship, isoequilibrium relationship and enthalpy-entropy compensation. Chem. Rev. 2001, 101, 673-696.
49. (c) Plake, H. R.; Sundberg T. B.; Woodward, A. R.; Martin, S. F. Design and synthesis of conformationally constrained, extended and reverse turn pseudopeptides as Grb2-SH2 domain antagonist. Tetrahedron Lett. 2003, 44, 1571-1574.
50. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997, 23, 3-25
51. (a) Veber, D. F.; Yamashita, D. S.; Oh, H.-J.; Smith, B. R.; Salyers, K. ; Levy, M.; Lee, C.-P.; Marzulli, A.; Smith, P.; Tomaszek, T.; Tew, D.; McQueney, M.; Stroup, G. B.; Lark, M. W.; James, I. E.; Gowen, M. Novel inhibitors of the osteoclast specific cysteine protease, cathepsin K. Peptides for the New Millennium, Proceedings of the American Peptide Symposium, 16th; June 26-July 1, 1999, Minneapolis, MN; Fields, G. B., Tam, J. P., Barany, G., Eds.; Kluwer Academic Publishers: Dordrecht, Netherlands, 2000; CODEN: 69ATHX Conference, pp 453-455.
52. (b) McQueney, M. S.; Feild, J.; Hanning, C. R.; Brun, K.; Ramachandran, K.; Connor, J.; Drake, F.; Jones, C. S.; Amegadzie, B. Y. Protein Expression Purif. 1998, 14 (3), 387-394.
53. (a) Mundy, G. R.; Roodman, G. D.; Bonewald, L. F.; Oreffo, R. O. C.; Boyce, B. F. Assays for bone resorption and bone formation. Methods Enzymol. 1991, 198 (Pept. Growth Factors, Pt. C), 502-510.
54. (b) Hahn, T. J.; Westbrook, S. L.; Halstead, L. R. Cortisol modulation of osteoblast metabolic activity in cultured neonatal rat bone. Endocrinology 1984, 114 (5), 1864-1870.
55. (c) Conaway, H. H.; Grigorie, D.; Lerner, U. H. Differential effects of glucocorticoid on bone resorption in neonatal mouse calvariae stimulated by peptide and steroid-like hormones. J. Endocrinol. 1997, 155, 513-521.